Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + interferon alpha-2b
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of cisplatin, a platinum-based chemotherapeutic agent, and interferon alpha-2b, a recombinant human interferon. Cisplatin works by crosslinking DNA, interfering with cell division and triggering apoptosis in cancer cells. Interferon alpha-2b has immunomodulatory, antiviral, and antiproliferative effects, binding to cell surface receptors and activating signaling pathways that inhibit cell proliferation. This combination has been studied in various cancers including hepatocellular carcinoma, biliary tract cancer, and mucosal melanoma.
- Other names
- PIAF regimen (when combined with doxorubicin and 5-fluorouracil)
02
Targets
DNAIFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on cisplatin + interferon alpha-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + interferon alpha-2b.